Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-eVax
- Development stage
- Discontinued
- Lead developer
- Takis
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
COVID-eVax is a synthetic DNA vaccine candidate developed for the prevention of COVID-19. It consists of an engineered DNA plasmid encoding a secreted monomeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The vaccine is administered intramuscularly and delivered via electroporation, which enhances cellular uptake of the DNA. Preclinical studies demonstrated that COVID-eVax induces strong neutralizing antibody responses against SARS-CoV-2, including variants of concern, as well as robust T cell responses. In animal models such as hACE2 transgenic mice and ferrets, it conferred significant protection against viral challenge by reducing weight loss, improving pulmonary function, and lowering viral replication in target organs. The vaccine has shown a favorable safety profile in preclinical toxicity studies and entered phase I/II clinical trials in Italy[1][3][4][5][7].
- Other names
- COVID eVax
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on COVID-eVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-eVax.